Grace Therapeutics, Inc. (GRCE) Stock Profile — Insider Trades & Financials

Net Income-$2.3M

EPS$-0.41

Market Cap$55.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Prashant Kohli

CEO & Executive Director

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The companyâs lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Founded: 2002
Employees: 6
Headquarters: Princeton, New Jersey, United States

⚡

Core Efficiency

ROE?

-3.57%

ROA?

-3.38%

D/E Ratio?

0.06

📊

Profitability Ratios

Current Ratio?

14.96

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

May 15, 2026 (in 36 days)

Quarterly Report (10-Q) — Based on filing pattern

May 15, 2026

Predicted10-Q

Feb 12, 2026

10-QQ3 20260d after period end

Nov 17, 2025

10-Q/AQ2 20264d after period end

Aug 12, 2025

10-QQ1 20261d after period end

Jun 23, 2025

10-KQ4 20254d after period end

Feb 19, 2025

10-Q/AQ3 20257d after period end

Nov 13, 2024

10-QQ2 20250d after period end

Aug 9, 2024

10-QQ1 20241d after period end

Jun 21, 2024

10-KQ4 20240d after period end

Loading company sections...

Grace Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness